Hamilton Wealth LLC lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 89.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,638 shares of the financial services provider’s stock after buying an additional 30,051 shares during the period. iShares Biotechnology ETF makes up 2.0% of Hamilton Wealth LLC’s holdings, making the stock its 15th biggest position. Hamilton Wealth LLC owned 0.13% of iShares Biotechnology ETF worth $10,740,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Citigroup Inc. raised its holdings in iShares Biotechnology ETF by 40.9% in the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock valued at $884,808,000 after acquiring an additional 1,521,992 shares during the last quarter. Morgan Stanley grew its position in shares of iShares Biotechnology ETF by 2.5% in the fourth quarter. Morgan Stanley now owns 3,204,126 shares of the financial services provider’s stock valued at $540,760,000 after purchasing an additional 76,978 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of iShares Biotechnology ETF by 11.4% in the fourth quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after purchasing an additional 218,066 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of iShares Biotechnology ETF by 27.2% in the third quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after purchasing an additional 226,852 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its position in iShares Biotechnology ETF by 286.2% during the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock worth $167,810,000 after buying an additional 736,881 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
NASDAQ IBB opened at $173.64 on Friday. The stock’s fifty day moving average is $170.57 and its two-hundred day moving average is $170.64. iShares Biotechnology ETF has a fifty-two week low of $123.61 and a fifty-two week high of $179.64.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Articles
- Five stocks we like better than iShares Biotechnology ETF
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
